PDF(Pubmed)
Abstract：
A series of structural constitutional arguments lodged in multiple cases against Centers for Medicare and Medicaid Services\' (CMS) authorities to negotiate prescription drug prices via the 2022 Inflation Reduction Act threaten the legitimacy of CMS program and federal agency powers.
摘要：
在多个案例中，针对医疗保险和医疗补助服务中心（CMS）当局通过2022年《降低通货膨胀法案》谈判处方药价格的一系列结构性宪法论点威胁到CMS计划和联邦机构权力的合法性。
